failure crash no fail rocket cancelled end
Biotech

GSK’s $700M Alector bet blows up with 2nd Alzheimer’s fail

GSK and Alector stopped a phase 2 trial of their Alzheimer’s drug after an interim analysis found the study was unlikely to hit its primary endpoint.
Nick Paul Taylor Apr 30, 2026 5:15am
dominoes stop stall halt end red

FDA hits Newron schizophrenia ph. 3 trial with hold after death

Apr 29, 2026 2:50pm
pine tree planting conservation vest forest care

AstraZeneca plucks EGFR degrader from Pinetree for $25M

Apr 30, 2026 2:29am
IPO initial public offering

Avalyn brings in $300M from oversized IPO

Apr 30, 2026 3:18am
AZ

AZ restarts £300M UK investment, but Merck not budging

Apr 29, 2026 10:01am
fundraise tracker 2026

Fierce Biotech Fundraising Tracker '26: Vivacta, Tortugas & more

Apr 29, 2026 9:30am
More News

Teva inks $700M Emalex buyout to bag near-approval Tourette drug

Apr 29, 2026 9:07am

AstraZeneca FLAP inhibitor flunks ph. 2 asthma trial

Apr 29, 2026 8:38am

Why the next blockbuster in GSK CEO's sights could be in cancer

Apr 29, 2026 7:16am

GSK walks away from $100M bet on Mersana STING ADC

Apr 29, 2026 6:16am